Olema Pharmaceuticals, Inc. - Common Stock (OLMA)

16.00
-5.55 (-25.75%)
NASDAQ · Last Trade: Mar 9th, 4:36 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
Top stock movements in today's session.chartmill.com
Via Chartmill · March 9, 2026
Monday's session: top gainers and loserschartmill.com
Via Chartmill · March 9, 2026
Wondering what's happening in today's pre-market session?chartmill.com
Via Chartmill · March 9, 2026
BETA Technologies, Starfighters Space And Other Big Stocks Moving Lower In Monday's Pre-Market Sessionbenzinga.com
U.S. stock futures lower, with Dow futures down over 1%. BETA Technologies (NYSE: BETA) fell in pre-market trading after reporting fourth-quarter results. Other stocks declining in pre-market trading include Zymeworks (NASDAQ: ZYME), Olema Pharmaceuticals (NASDAQ: OLMA), Brand Engagement Network (NASDAQ: BNAI), Aura Biosciences (NASDAQ: AURA), Tevogen Bio Holdings (NASDAQ: TVGN), ArcelorMittal SA (NYSE: MT), Invivyd (NASDAQ: IVVD), ORIC Pharmaceuticals (NASDAQ: ORIC), York Space Systems (NYSE: YSS), and Heartland Express (NASDAQ: HTLD).
Via Benzinga · March 9, 2026
Structure Therapeutics Stock Soars Over 200% as One Fund Adds to a $242 Million Positionfool.com
Structure Therapeutics develops oral drugs for chronic diseases, with lead assets targeting diabetes, obesity, and cardiovascular care.
Via The Motley Fool · February 25, 2026
Protagonist Stock Up 120%, but One Fund Just Revealed a $170 Million Exitfool.com
This biotech innovator develops peptide-based therapies for blood and immune disorders, advancing a pipeline of clinical-stage candidates.
Via The Motley Fool · February 25, 2026
Disc Medicine Stock Is Swinging, but This Fund's New $52 Million Bet Shows Convictionfool.com
Disc Medicine develops therapies for rare blood disorders, leveraging clinical-stage biotech expertise in red blood cell biology.
Via The Motley Fool · February 25, 2026
Cashing In at the Peak: Olema Pharmaceuticals Insiders Sell $8 Million in Stock After 300% Surge
Olema Pharmaceuticals (NASDAQ:OLMA) has become the latest focal point of biotech volatility and executive opportunism. Following a staggering 300% surge in its share price over the past year—fueled by a "rising tide" effect in the breast cancer treatment market—top insiders have begun offloading significant portions of their
Via MarketMinute · January 9, 2026
Olema Insider Sells $8 Million in Shares After 300% Stock Surgefool.com
Focused on therapies for women's cancers, this clinical-stage biotech reported a significant insider sale amid a year of sharp stock gains.
Via The Motley Fool · January 9, 2026
In today's session, these stocks are experiencing unusual volume.chartmill.com
On Thursday, there are stocks with unusual volume. Let's take a look.
Via Chartmill · November 20, 2025
Investment Powerhouse Backs Biotech Stock to the Tune of $419 Millionfool.com
Bain Capital added more than 12.4 million shares of HeartFlow stock in the thrid quarter
Via The Motley Fool · November 20, 2025
Keep an eye on the top gainers and losers in Thursday's session.chartmill.com
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Via Chartmill · November 20, 2025
12 Health Care Stocks Moving In Thursday's Intraday Sessionbenzinga.com
Via Benzinga · November 20, 2025
Nutex Health Posts Strong Q3 Results, Joins PACS Group, Walmart, Cerence And Other Big Stocks Moving Higher On Thursdaybenzinga.com
Via Benzinga · November 20, 2025
Institutional Titan Hits the Jackpot: Biotech Stock Surges by 116% on Buyout Offerfool.com
Bain Capital's bet on Cidara Therapeutics stocks has paid off in a big way
Via The Motley Fool · November 20, 2025
In today's session, these stocks are experiencing unusual volume.chartmill.com
Let's explore the current happenings on the US markets on Wednesday. Below, you'll find the stocks exhibiting unusual volume in today's session.
Via Chartmill · November 19, 2025
Biotech Stock Gets Booted in Latest Fund Updatefool.com
Bain Capital sold its entire stake in Nuvalent stock during the third quarter.
Via The Motley Fool · November 19, 2025
Portfolio Adjustment: Institutional Heavyweight Exits Biotech Stockfool.com
Bain Capital completely exited its position in Disc Medicine stock during the third quarter
Via The Motley Fool · November 19, 2025
Which stocks are moving on Tuesday?chartmill.com
Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements.
Via Chartmill · November 18, 2025
Why Bain Capital Is Selling Shares of This Biotech Stock Nowfool.com
Bain Capital sold $20 million worth of Pharvaris stock during the third quarter.
Via The Motley Fool · November 18, 2025
Which stocks are most active on Tuesday?chartmill.com
Discover the most active stocks in Tuesday's session. Stay informed about the stocks that are generating the most trading volume!
Via Chartmill · November 18, 2025
Top movers in Tuesday's sessionchartmill.com
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.
Via Chartmill · November 18, 2025
12 Health Care Stocks Moving In Tuesday's Intraday Sessionbenzinga.com
Via Benzinga · November 18, 2025
Pharma Bro Martin Shkreli Shorts Olema Pharmaceuticals Stockbenzinga.com
"Pharma Bro' and notorious bear Martin Shkreli is shorting Olema Pharmaceuticals stock.
Via Benzinga · November 18, 2025
Let's uncover which stocks are experiencing notable gaps during today's session.chartmill.com
Today's session on Tuesday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.
Via Chartmill · November 18, 2025